University of Dundee

New insights into nuclear factor erythroid 2-related factors in toxicology and pharmacology

Pi, Jingbo; Hayes, John D.; Yamamoto, Masayuki

Published in:
Toxicology and Applied Pharmacology

DOI:
[10.1016/j.taap.2019.01.014](https://doi.org/10.1016/j.taap.2019.01.014)

Publication date:
2019

Licence:
CC BY-NC-ND

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Pi, J., Hayes, J. D., & Yamamoto, M. (2019). New insights into nuclear factor erythroid 2-related factors in toxicology and pharmacology. *Toxicology and Applied Pharmacology*, 367, 33-35.
<https://doi.org/10.1016/j.taap.2019.01.014>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1 **New Insights into Nuclear factor erythroid 2-related factors in**

2 **Toxicology and Pharmacology**

3 The cap'n'collar-basic region leucine zipper (CNC-bZIP) family of transcription factors
4 includes the founding member Nuclear factor-erythroid 2 (NF-E2) p45, NF-E2 p45-related factor
5 1 (Nrf1; also known as NFE2L1, LCRF1, TCF11, HBZ17 or FLJ00380), Nrf2 and Nrf3 (also
6 abbreviated as NFE2L2 and NFE2L3, respectively), and the more distantly related members BTB
7 (i.e., Broad complex, Tramtrack, and Bric-à-Brac) domain and CNC homolog 1 (BACH1) and
8 BACH2 (Tebay *et al.*, 2015; Katsuoka and Yamamoto, 2016; Zhang and Xiang, 2016; Zhu *et al.*,
9 2016; Yamamoto *et al.*, 2018). In the last two decades, our understanding of CNC-bZIP proteins
10 has advanced enormously, and our appreciation of their physiological significance has similarly
11 increased. The primary objective of this special issue (SI) is to stimulate continuing effort to
12 understand the toxicological and pharmacological roles of CNC-bZIP proteins, and that of Nrf2
13 and Nrf1 in particular.

14 Nrf2 is normally found in the cytoplasm of mammalian cells, where it associates with the
15 redox-sensitive Kelch-like ECH-associated protein 1 (Keap1) E3 ubiquitin ligase substrate
16 adaptor that polyubiquitinylates Nrf2 and targets it for proteolytic degradation by the 26S
17 proteasome. This mechanism keeps cellular Nrf2 levels low and prevents Nrf2 accumulation in
18 the nucleus where it would mediate signaling effects (Suzuki and Yamamoto, 2017; Yamamoto *et al.*,
19 2018). In response to a wide variety of oxidative and electrophilic insults, Nrf2 avoids Keap1-
20 mediated proteolytic digestion and accumulates in the nucleus where it heterodimerizes with
21 small musculoaponeurotic fibrosarcoma (MAF) proteins and binds to antioxidant response
22 element (ARE; 5'-TGACNNNGC-3') sequences within target genes, resulting in expression of
23 that gene for a limited period (Suzuki and Yamamoto, 2017; Yamamoto *et al.*, 2018). The target

genes of Nrf2 include those that encode a variety of antioxidant and detoxification enzymes. Thus, the Keap1-Nrf2 system is recognized as a key player in controlling biochemical defense against exogenous and endogenous electrophilic and oxidative stressors. Importantly, accumulating evidence indicates that Nrf2 also plays critical roles in regulating expression of numerous genes involved in cell metabolism, proliferation and differentiation ((Pi *et al.*, 2010; Xue *et al.*, 2013; Murakami and Motohashi, 2015).

In the Review section of this SI, Ryoo and Kwak revisited recent experimental observations on the relationship between Nrf2 and mitochondria and discussed mechanisms by which Nrf2 controls mitochondria and metabolism in cancer cells. These authors report that Nrf2 is positively associated with mitochondrial biogenesis through direct upregulation of mitochondrial transcription factors and is involved in the mitochondrial quality control system via activation of mitophagy. Additionally, Nrf2 modulation in cancer cells leads to changes in the mitochondrial respiratory system and cancer bioenergetics that overall affect cancer metabolism. Ikehata and Yamamoto reviewed recent progress in the study of contributions by Nrf2 and related factors to protection against ultraviolet radiation (UVR). The Keap1-Nrf2 system is not always efficient in responding to UVR, especially to short wavelengths such as UVC and UVB, indicating that UVR is a poor activator of the Keap1-Nrf2 system. However, sustained activation of Nrf2 appears to suppress the harmful effects of chronic UVR exposure, such as photoaging and carcinogenesis in the skin, indicating that Nrf2 activation is beneficial for the protection of the skin from the harmful effects of UVR. However, sustained activation of Nrf2 may also adversely affect the skin, especially in the case of UVR-induced carcinogenesis. Sun *et al.* assessed the roles of Nrf2 in the development of alcoholic liver disease (ALD) and emphasized that Nrf2 in different cell types in the liver may play paradoxical roles in the progression of ALD. In the early stages of ALD, Nrf2 in hepatocytes plays a crucial role in regulating redox balance and lipid metabolism. With the

48 progression to steatohepatitis, the role of Nrf2 in Kupffer cells become evident, which alleviates
49 the inflammatory response in the liver. During end-stage ALD, Nrf2 in hepatic stellate cells may
50 be critical in modulating fibrogenesis. In light of the important protective roles of Nrf2 against
51 oxidative damage, the study and validation of possible pharmacological targets that would restore
52 the coordination of the networks in related pathologies has recently received particular attention.
53 In the review by Yamawaki *et al.*, they summarized the current issues in the treatment of kidney
54 diseases, Nrf2 activators as treatment options, and perspectives on pharmaceutical applications of
55 Nrf2 activators.

56 In the Research Articles section of this SI, Raghunath *et al.* identified ARE sequences in all
57 protein-coding genes in the zebrafish genome. They found multiple unique AREs that have not
58 been reported previously in cytoprotective genes of this organism. In a detailed mechanistic study,
59 McMahon *et al.* uncovered that Keap1 directly senses Zn^{2+} through a cluster of amino-acids that
60 include His-225, Cys-226 and Cys-613. They presented evidence that binding of Zn^{2+} triggers a
61 conformational switch in Keap1, which is envisaged to perturb the architecture of the cullin-3
62 RING ubiquitin ligase (CRL) complex $\text{CRL}^{\text{Keap1}}$, such that bound Nrf2 becomes mis-aligned with
63 respect to the ubiquitin-charged E2 enzyme. The data are consistent with the notion that Keap1
64 possesses a Zn^{2+} sensor whose triggering distorts its structure in a fashion that inhibits
65 ubiquitylation of Nrf2 upon the $\text{CRL}^{\text{Keap1}}$ complex. Chen's group explored the role of Nrf2 in
66 mediating aberrant hematopoiesis in response to low-dose benzene exposure in *Nrf2*-KO mice.
67 They found that the hematotoxicity of low-dose benzene seems to decrease in *Nrf2*-KO mice
68 based on peripheral blood cell counts, despite the fact that oxidative and DNA damage was
69 significantly enhanced in the mutant mice. In addition, deficiency of Nrf2 triggered proliferation
70 and differentiation of hematopoietic cells by accelerating cell cycle progression and induced a
71 morphological abnormality in peripheral erythrocytes and bone marrow cells, implicating

compensatory changes that allow induction of dysfunctional defective blood cells. In an *in vitro* study, Meng's group reported that rat primary microglia and astrocytes display different responses to lead toxicity. In another *in vitro* study, Zhao's group examined the role of the Nrf2 signaling pathway in the cytotoxicity induced by the hypoxia mimetic cobalt chloride (CoCl₂) in human keratinocyte HaCaT cells. These workers found that stable knockdown (KD) of Nrf2 dramatically reduced expression of antioxidant enzymes and sensitized the cells to acute CoCl₂-induced oxidative stress and cytotoxicity, whereas *Keap1*-KD cells showed enhanced expression of ARE-driven genes and resistance to CoCl₂-induced cell damage. In addition, pretreatment of HaCaT cells with *tert*-butylhydroquinone protected these cells from CoCl₂-induced cell injury in an Nrf2-dependent fashion. In a systematic *in vivo* study, Cho *et al.* demonstrated that sulforaphane (SFN) significantly reduced acute lung injury-like phenotypes caused by subsequent hyperoxia exposure in an Nrf2-dependent manner. Differential lung transcriptome changes induced by SFN in wildtype and *Nrf2*-KO mice suggested that it acts through Nrf2 enhancing pulmonary mitochondrial dynamics and metabolism to maintain the bioenergetic demands of lung cells against oxidative stress. As a part of a series of studies on ARE inhibitors from Pi's laboratory, Zhu *et al.* identified a traditional Chinese medicine, triptolide, as an effective and potent Nrf2-ARE inhibitor. Importantly, triptolide, at non-toxic levels, markedly sensitized non-small-cell lung cancer cells to chemotherapeutic treatments *in vitro* and in a xenograft mouse tumor model.

Nrf1 serves as a unique vital player in maintaining cellular homeostasis and organ integrity during normal development and cell growth throughout life. Global loss of Nrf1 results in severe oxidative stress, genomic instability, embryonic lethality and developmental disorders. Conditional knockout of Nrf1 results in adult diseases such as non-alcoholic steatohepatitis, hepatocellular carcinoma, pancreatic β -cell and adipocyte dysfunction and neurogenerative

diseases (Pi *et al.*, 2010; Xue *et al.*, 2013; Murakami and Motohashi, 2015; Zheng *et al.*, 2015; Kim *et al.*, 2016; Fu *et al.*, 2018; Hou *et al.*, 2018; Wang *et al.*, 2018). Thus, Nrf1 is critically implicated in a variety of important physio-pathological processes by governing expression of crucial genes in order to reinforce antioxidant, detoxification and cytoprotective responses to cellular stress. Of clinical interest, Nrf1 mediates the proteasomal 'bounce-back' response, leading to drug resistance to proteasomal inhibitors for clinical treatment of neuroblastoma, multiple myeloma and triple-negative breast cancers (Steffen *et al.*, 2010; Bugno *et al.*, 2015; Sekine *et al.*, 2018). During its translation, Nrf1 is targeted to the endoplasmic reticulum (ER) and subject to extensive post-translational modification before it regulates its target genes. However, the mechanisms whereby Nrf1 is processed and topologically released from the ER before entering the nucleus is hotly debated. In this SI, a series of experiments from Zhang's laboratory demonstrate the maturation processing of Nrf1 to remove its N-terminal ~12.5-kDa and longer polypeptides. The authors have further elucidated topo-vectorial mechanisms that monitor dynamic movement of Nrf1 in and out of the ER lumen, as well as the selective proteolytic processing of the CNC-bZIP protein to remove distinct lengths of its NTD (most of which was refolded as a UBL module) and PEST-adjointing AD1 domains. More importantly, they have also established a general criterion acceptable for identification of the endogenous Nrf1 α /TCF11 and derivative isoforms, with distinct molecular weights and half-lives determined in various experimental cellular settings. Furthermore, they propose that coupled positive and negative feedback circuits exist between Nrf1 and its target genes. These results suggest Nrf1 is subject to dual opposing control in which low doses of proteasomal inhibitors elicit a 'bounce-back' response but higher doses inhibit the transcription factor. Collectively, the findings from Zhang's group suggest the potential of Nrf1 to be developed as a new target for chemoprevention and therapy of cancers and other diseases.

Coordinately dealing with fluctuating levels of numerous metabolic and environmental stresses is critical for the survival of cells and whole organisms. Perturbations in redox balance may impair cellular homeostasis and trigger the onset of disease. Accordingly, cells have developed multiple and well-conserved mechanisms that regulate adaptive antioxidant responses. Oxidative stress, which is defined as a general response to internal and environmental oxidative challenges, is involved in triggering adaptation to oxidative damage. On the other hand, persistent oxidative stress may lead to disruption of redox signaling and loss of homeostatic mechanisms (Zhang *et al.*, 2010; Fu *et al.*, 2016). Thus, precise coordination of cellular adaptive responses to oxidative insults promotes stress resistance and recovery of homeostasis, whereas persistent adaptation would have a cost that may be involved in the pathogenesis of many chronic disorders (see Figure 1).

For many decades, ROS were considered cytotoxic waste products arising from cellular processes. Thus, antioxidant interventions were established in the settings of aging and chronic diseases. However, animal studies and epidemiological investigations on the therapeutic outcomes of antioxidant interventions have provided data that contradict the view that ROS are merely of toxicological significance, questioning long-standing beliefs of an ultimate beneficial role for antioxidant therapies in health and disease (Zhang *et al.*, 2010; Fu *et al.*, 2016). In agreement with the aforementioned accumulating evidence and in the context of major chronic diseases, we reasonably hypothesized that persistent activation of Nrfs-ARE caused by environmental stressors may be involved in the pathogenesis of various chronic diseases, such as Type 2 diabetes and malignant tumors (see Figure 1). Of course, coordinated efforts are needed to clarify the exact roles of various isoforms of Nrfs in the development and intervention of various chronic diseases.

In summary, while significant progress has been made in terms of elucidating how the different Nrf transcription factors (in particular Nrf2, and to a much lesser extent Nrf1) regulate the antioxidant response, critical questions still remain. Most obviously, we know relatively little about NF-E2 p45, Nrf3, BACH1 and BACH2. Other important open issues relating to Nrfs in toxicology and pharmacology may include, but are not limited to: (1) determining the spectrum of target genes of Nrfs in different cells under diverse stress challenges, and the potential involvement of Nrfs in regulating genes independently of ARE sequences; (2) the mechanistic aspects of the complex regulatory network of Nrfs-mediated transcription under basal physiological conditions and under adaptive response conditions; (3) the transcriptional regulation of Nrfs under a sustained stress challenge, in particular the involvement of non-coding RNAs, such as miRNAs; (4) the crosstalk between Nrfs and other stress response machinery in response to various internal and environmental challenges; (5) the toxicological significance and application of Nrfs network perturbation in toxicity testing; (6) the characterization of the cell-specific physiological functions of different isoforms of Nrf1; (7) identification and application of novel modulators targeting specifically the transcriptional activity of various isoforms of Nrfs; (8) precise phenotyping of cell-specific knockout or overexpression of Nrfs in a variety of disease models; and (9) identification and characterization of functional SNPs and epigenetic sites in the human genes of Nrfs.

Guest-Editors:

Jingbo Pi, M.D., Ph.D.

School of Public Health,

China Medical University

166 P.R. China
167 Phone: 0086-18900910300
168 Email: jbpi@cmu.edu.cn; jingbopi@163.com

169

170 **John D Hayes, Ph.D**

171 Jacqui Wood Cancer Centre,
172 Division of Cellular Medicine,
173 Ninewells Hospital and Medical School,
174 University of Dundee, Dundee DD1 9SY,
175 Scotland,
176 U.K.

177 Email: j.d.hayes@dundee.ac.uk

178

179 **Masayuki Yamamoto, Ph.D**

180 Department of Medical Biochemistry,
181 Tohoku University Graduate School of Medicine,
182 Sendai 980-8575,
183 Japan

184 Email: masiyamamoto@med.tohoku.ac.jp

185

186

187 **References :**

- 188 Bugno, M., Daniel, M., Chepelev, N. L., and Willmore, W. G. (2015). Changing gears in
189 Nrf1 research, from mechanisms of regulation to its role in disease and
190 prevention. *Biochimica et biophysica acta* **1849**, 1260-1276.
- 191 Fu, J., Hou, Y., Xue, P., Wang, H., Xu, Y., Qu, W., Zhang, Q., and Pi, J. (2016). Nrf2 in
192 Type 2 diabetes and diabetic complications: Yin and Yang *Current Opinion in*
193 *Toxicology* **1**, 9-19.
- 194 Fu, J., Zheng, H., Cui, Q., Chen, C., Bao, S., Sun, J., Li, L., Yang, B., Wang, H., Hou, Y.,
195 Xu, Y., Xu, Y., Zhang, Q., and Pi, J. (2018). Nfe2l1-silenced insulinoma cells
196 acquire aggressiveness and chemoresistance. *Endocrine-related cancer* **25**, 185-
197 200.
- 198 Hou, Y., Liu, Z., Zuo, Z., Gao, T., Fu, J., Wang, H., Xu, Y., Liu, D., Yamamoto, M., Zhu,
199 B., Zhang, Y., Andersen, M. E., Zhang, Q., and Pi, J. (2018). Adipocyte-specific
200 deficiency of Nfe2l1 disrupts plasticity of white adipose tissues and metabolic
201 homeostasis in mice. *Biochemical and biophysical research communications* **503**,
202 264-270.
- 203 Katsuoka, F., and Yamamoto, M. (2016). Small Maf proteins (MafF, MafG, MafK):
204 History, structure and function. *Gene* **586**, 197-205.
- 205 Kim, H. M., Han, J. W., and Chan, J. Y. (2016). Nuclear Factor Erythroid-2 Like 1
206 (NFE2L1): Structure, function and regulation. *Gene* **584**, 17-25.
- 207 Murakami, S., and Motohashi, H. (2015). Roles of Nrf2 in cell proliferation and
208 differentiation. *Free radical biology & medicine* **88**, 168-178.
- 209 Pi, J., Leung, L., Xue, P., Wang, W., Hou, Y., Liu, D., Yehuda-Shnaidman, E., Lee, C.,
210 Lau, J., Kurtz, T. W., and Chan, J. Y. (2010). Deficiency in the nuclear factor E2-
211 related factor-2 transcription factor results in impaired adipogenesis and protects
212 against diet-induced obesity. *The Journal of biological chemistry* **285**, 9292-9300.
- 213 Sekine, H., Okazaki, K., Kato, K., Alam, M. M., Shima, H., Katsuoka, F., Tsujita, T.,
214 Suzuki, N., Kobayashi, A., Igarashi, K., Yamamoto, M., and Motohashi, H.
215 (2018). O-GlcNAcylation Signal Mediates Proteasome Inhibitor Resistance in
216 Cancer Cells by Stabilizing NRF1. *Molecular and cellular biology*.
- 217 Steffen, J., Seeger, M., Koch, A., and Kruger, E. (2010). Proteasomal degradation is
218 transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop.
219 *Molecular cell* **40**, 147-158.
- 220 Suzuki, T., and Yamamoto, M. (2017). Stress-sensing mechanisms and the physiological
221 roles of the Keap1-Nrf2 system during cellular stress. *The Journal of biological*
222 *chemistry* **292**, 16817-16824.
- 223 Tebay, L. E., Robertson, H., Durant, S. T., Vitale, S. R., Penning, T. M., Dinkova-
224 Kostova, A. T., and Hayes, J. D. (2015). Mechanisms of activation of the
225 transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and
226 the pathways through which it attenuates degenerative disease. *Free radical*
227 *biology & medicine* **88**, 108-146.

- Wang, H., Zhu, J., Liu, Z., Lv, H., Lv, P., Chen, F., Fu, J., Hou, Y., Zhao, R., Xu, Y., Zhang, Q., and Pi, J. (2018). Silencing of long isoforms of nuclear factor erythroid 2 like 1 primes macrophages towards M1 polarization. *Free radical biology & medicine* **117**, 37-44.
- Xue, P., Hou, Y., Chen, Y., Yang, B., Fu, J., Zheng, H., Yarborough, K., Woods, C. G., Liu, D., Yamamoto, M., Zhang, Q., Andersen, M. E., and Pi, J. (2013). Adipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. *Diabetes* **62**, 845-854.
- Yamamoto, M., Kensler, T. W., and Motohashi, H. (2018). The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. *Physiological reviews* **98**, 1169-1203.
- Zhang, Q., Pi, J., Woods, C. G., and Andersen, M. E. (2010). A systems biology perspective on Nrf2-mediated antioxidant response. *Toxicol Appl Pharmacol* **244**, 84-97.
- Zhang, Y., and Xiang, Y. (2016). Molecular and cellular basis for the unique functioning of Nrf1, an indispensable transcription factor for maintaining cell homeostasis and organ integrity. *The Biochemical journal* **473**, 961-1000.
- Zheng, H., Fu, J., Xue, P., Zhao, R., Dong, J., Liu, D., Yamamoto, M., Tong, Q., Teng, W., Qu, W., Zhang, Q., Andersen, M. E., and Pi, J. (2015). CNC-bZIP protein Nrf1-dependent regulation of glucose-stimulated insulin secretion. *Antioxid Redox Signal* **22**, 819-831.
- Zhu, J., Wang, H., Chen, F., Fu, J., Xu, Y., Hou, Y., Kou, H. H., Zhai, C., Nelson, M. B., Zhang, Q., Andersen, M. E., and Pi, J. (2016). An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy. *Free radical biology & medicine* **99**, 544-556.

254 **Figure legends :**

255 **Figure 1. Nrfs may play paradoxical *Yin-and-Yang* roles in the development of oxidative**
256 **stress-related disorders.** *Yin*-side of ROS: Prolonged overproduction of ROS may result in
257 oxidative damage and even cell death, leading to impaired cell function; *Yang*-side of ROS:
258 Transient ROS production in response to various stimuli may function as signals mediating
259 cellular responses. *Yin*-side of antioxidants: Antioxidants may blunt ROS signaling in the cell;
260 *Yang*-side of antioxidants: Antioxidants may generally protect cells against oxidative damage.
261 *Yin*-side of Nrfs: Chronic activation of Nrfs-mediated antioxidant response under persistent
262 oxidative stress may blunt normal ROS signaling in the cell; *Yang*-side of Nrfs: Nrfs activation
263 and subsequent induction of antioxidants may protect cells from oxidative damage.